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Purpose/Objective: Real-time adaptive radiotherapy aims to 
improve radiation treatment through re-optimisation of 
treatment delivery based on patient-specific changes in 
anatomy and biology during treatments. MLC tracking is one 
real-time adaptive strategy that applies real-time tumour 
localisation to adapt the MLC shape during treatment. MLC 
tracking has been shown to be feasible for prostate cancer 
treatment on a standard linac, leading to improved tumour 
dose conformity, reduced rectal dose and improved fidelity 
of the planned treatment compared to standard delivery. 
Patient specific quality assurance of MLC tracking treatment 
is complex due to daily variation in tumour motion track 
creating new adaptations each day. We propose a high 
temporal and spatial resolution dosimetry system to verify 
the performance of MLC tracking.  
Materials and Methods: A monolithic silicon detector, known 
as MagicPlate-512 (MP512), has been developed and 
comprises 512 pixels arranged in a square array with sensitive 
volume 0.5x0.5x0.1mm3 and pitch 2mm. The array allows 
high resolution dose mapping and dose profiling in 2D. The 
MP512 is read out by a data acquisition system (DAS) 
synchronised with the electron gun pulses of the linac for 
pulse by pulse resolution of the dose delivered by the 
treatment beam. The detector is embedded in a solid water 
phantom and installed on a movable platform. The platform 
is supplied with a patient-specific motion pattern to replicate 
tumour motion. An electromagnetic positioning system 
provides real time position information to the MLC tracking 
software. The dose delivered by a static gantry with MLC 
defined square fields of sizes 1x1, 2x2 and 3x3cm2 is 
measured by MP512 and compared to EBT3 film for cases 
without motion, with motion and with motion and MLC 
tracking enabled. The DAS enables verification of dose 
variation pulse by pulse for each pixel, providing an insight 
into beam delivery for optimisation or debugging of a plan. 
Results: The beam profiles along the y-axis of the detector 
are compared to the EBT3 film for the three motion cases for 
the 2x2cm2 MLC defined field. 
 
 
The penumbral width (80-20%) and full-width at half-
maximum is measured for each profile for the field sizes and 
motion cases, the results benchmarked by EBT3 film. 
 
 
 
Conclusions: The results measured by the MP512 show 
excellent agreement with EBT3 film. The motion is observed 
to smear the profile of the beam. MP512 and EBT3 are able 
to reconstruct the distortion within 0.2mm; with MLC 
tracking enabled the smearing is reduced with a good 
agreement between no-motion and motion-tracking. The 
MP512 detector has proven to be an effective tool for pre-
treatment verification of real-time adaptive deliveries with 
both high spatial resolution for dose profiling and high 
temporal resolution for pulse by pulse reconstruction. 
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Purpose/Objective: The objective of this study was to 
directly measure and compare kQ factors [1] of reference 
type ionization chambers in flattening-filter (FF) and 
flattening-filter-free (FFF) clinical photon beams with 
nominal energies of 6 and 10 MV. 
Materials and Methods: Eight Baldwin-Farmer type ionization 
chambers (2×PTW 30013, 3×NE 2571, 3×PTW 30012) were 
calibrated in terms of absorbed-dose-to-water, Dw, in 60Co at 
VSL and in four clinical photon beams of 6 and 10 MV, both FF 
and FFF of an Elekta Versa HD at the Netherlands Cancer 
Institute. The absorbed-dose-to water was determined with 
the new VSL water calorimeter, designed for on-site 
measurements in clinical teletherapy beams (see Figure). 
Two waterproof ionization chambers (PTW 30013) were 
directly calibrated inside the water calorimeter thermostat. 
The other six ionization chambers (not waterproof) were 
cross-calibrated in a reference phantom against the PTW 
30013 chambers. Both the calorimeter and chamber 
measurements were performed against an external 
transmission monitor, placed on the accelerator tray. 
Measurements were corrected for radial non-uniformity due 
to the lateral beam profile with respect to the measurement 
point in the water calorimeter and the measurement volume 
of the ionization chamber. 
The FF and FFF beams of the same nominal energy were 
matched with respect to pdd(10). Based on pdd(10) the 
measured kQ factors in the two FFF beams were compared 
directly with the FF beams of the same nominal energy. 
Additionally a comparison between kQ factors in FFF and FF 
beams based on quality index TPR20,10 for both beams was 
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made using an existing code of practice for non-FFF beams, 
NCS-18 [1]. Therefore kQ values were obtained provided by 
the code of practice. The differences of the NCS-18 kQ values 
between FFF and FF beams were compared with the 
measured differences. 
 
 
 
Results: The average kQ of the six NCS-18 recommended 
chambers (i.e. the not waterproof types) are presented in 
the Table. Comparison between FFF and FF beams of the 
same nominal energy and pdd(10) show negligible differences 
of -0.001 (8) and 0.000 (9) for 6 and 10 MV respectively. 
Based on NCS-18, using quality index TPR20,10 the differences 
in kQ also show negligible deviations of respectively -0.002 (8) 
and -0.003 (9). The uncertainties, represented as the last 
significant digit between brackets, are reported with a 
coverage factor, k = 2. 
 
 
Conclusions: The differences between FFF and FF clinical 
photon beams of 6 and 10 MV for measured kQ values of six 
reference type ionization chambers with the same value for 
the beam quality index pdd(10) are negligible (< 0.001). 
Application of a TPR20,10 based protocol results in slightly 
higher differences (< 0.003). All differences are within the 
reported uncertainties. 
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Purpose/Objective: The combined simultaneous use of MRI 
and MV photon irradiations is one of the most promising 
innovations of cancer radiotherapy as it offers the capability 
of using non-ionizing radiation for high quality imaging with 
tissue selectivity to drive the delivery of therapeutic doses of 
ionizing radiation to tumour volumes. Clinical application of 
such facilities presents new dosimetric and radiobiological 
challenges. 
The aim of this work was to use 4 different chamber types 
and alanine dosimeters to determine correction factors and 
optimum set up for ionization chamber based dosimetry in an 
MR-linac. 
Materials and Methods: Measurements were made in the 
UMC Utrecht MR-linac facility (Elekta). Absorbed dose was 
measured at the isocentre in a static vertical beam, with the 
detector axis perpendicular to both the beam and magnetic 
field. A 10 cm x 10 cm field was set at the isocentre and 
measurements were made at 5cm depth in a water-
equivalent full scatter phantom. The chambers used were a 
PTW Farmer-type chamber (TW30012-1), a PTW waterproof 
Farmer-type chamber (TW30013), a 2611-type chamber and 
an Exradin A1SL chamber. Alanine pellets were used in a 
Farmer-shaped PEEK holder. 
Measurements were made in the conventional way to 
determine the corrections required for the effects due to 
both polarity and ion recombination. To investigate machine 
linearity, 500 – 5000MU were delivered to alanine pellets. 
Results: The alanine dosimeters used in the UMC-Utrecht MR-
linac were used to calibrate the MR-linac output. This was 
determined in terms of cGy / MU, using machine monitor 
units as the reference, as well as in terms of cGy / monitor 
chamber nC. The machine calibration was used to determine 
the dose delivered to each ionization chamber. For the same 
beams, each chamber also measured the total dose 
delivered. These results are shown in table 1. 
 
Table 1. The dose as measured by each of four ionisation 
chambers compared to the dose determined via calibration of 
the MR-linac output using alanine. 
Conclusions: The two Farmer chamber calibrations deviate 
from the alanine based calibration by 1.9% and measure a 
greater dose than the alanine. The 2611 chamber differs from 
the alanine measurement by 0.3% and measures a smaller 
dose than the alanine. The A1SL chamber differs by 2% from 
the alanine, measuring a smaller dose for the same 
conditions. 
The effect of a 1.5 T field on the polarity and ion 
recombination corrections was expected to be small (Smit et 
al. 2013) and the results of this work agree with this for all 
chamber types. Within uncertainty, the dose response of 
alanine and the 2611 monitor ionization chamber was linear 
with delivered monitor units. 
The correction for the effect of the magnetic field will be 
determined by measurements on a theratron cobalt-60 
facility which has just had a 1.5T magnet installed. 
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